Alnylam Pharmaceuticals Prices Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Alnylam Pharmaceuticals (ALNY) PT Lowered to $152 at Piper Jaffray Following Offering
January 15, 2019 4:34 PM ESTPiper Jaffray analyst Edward Tenthoff lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $152.00 (from $160.00) while maintaining a Overweight rating following equity raise.
... More